期刊文献+

甲状腺手术“偶然”检出73例微小乳头状癌的回顾性分析

Retrospective analysis 73 cases of incidental papillary thyroid microcarcinoma on presumed benign thyroid diseases
下载PDF
导出
摘要 【目的】分析甲状腺微小乳头状癌(PTMC)在行良性甲状腺疾病(BTD)手术中的“偶然”检出率,及其与患者年龄、性别、合并发生的甲状腺病变类型的关系,以期发现PTMC的潜在预测因素。【方法】收集本院2015年1月1日至2015年12月31日期间因甲状腺疾病行外科手术治疗的共939名患者的病例资料,回顾性分析其临床病理特点。【结果】939名患者中男性194名(20.7%),女性745名(79.3%);年龄范围11~84岁。73名经病理切片确诊为PTMC,男性15名(7.1%),女性58名(7.5%);年龄范围18~66岁。采用Pearson卡方检验,PTMC的总“偶然”检出率为7.8%,且与患者年龄、性别的关联无统计学意义(P>0.05)。73名PTMC患者中26名无合并良性病变;33名合并结节性甲状腺肿;6名合并慢性淋巴细胞性甲状腺炎;2名合并毒性结节性/弥漫性甲状腺肿。采用单变量logistic回归分析,结节性甲状腺肿(OR=0.115,95%CI=0.064-0.206,P<0.001)是“偶然”检出率的阴性预测因素,毒性结节性/弥漫性甲状腺肿(OR=0.085,95%CI=0.019-0.379,P=0.001)是“偶然”检出率的阴性预测因素,差异均有统计学意义(P<0.001)。采用多变量logistic回归分析,结节性甲状腺肿(OR=0.102,95%CI=0.055-0.189,P<0.001)和毒性结节性/弥漫性甲状腺肿(OR=0.090,95%CI=0.020-0.401,P=0.002)可视为PTMC独立的潜在阴性预测因素,差异均有统计学意义(P<0.001)。【结论】PTMC“偶然”检出率与患者年龄、性别均无关。结节性甲状腺肿合并PTMC的检出率在所有甲状腺病变中最高,而毒性结节性/弥漫性甲状腺肿合并PTMC最低。结节性甲状腺肿和毒性结节性/弥漫性甲状腺肿可视为PTMC独立的潜在阴性预测因素。 【Objective】The aim of this study was to retrospectively investigate the incidence of papillary thyroid microcarcinoma(PTMC)in patients operating for presumed benign thyroid disease(BTD)and its relation to age,sex,and types of benign thyroid lesions,to determine potential independent predictors for PTMC.【Methods】A total number of 939 patients who underwent thyroid surgery during the year 2015 were enrolled in the study,a retrospective analysis was conducted to assess their clinical and pathological characteristics.【Results】In totle 939 cases there were 194(20.7%)males and 745(79.3%)females,age ranged from 11 to 84 years.In 73 cases of PTMC there were 15(7.1%)males and 58(7.5%)females,age ranged from 18 to 66 years.The overall incidence of PTMC was 7.8%.According to Pearson's Chi-Square test,sex and age were not significantly related to the incidence of PTMC(P>0.05).According to univariate logistic regression,the highest incidence of PTMC was in multinodular goiter(OR=0.115,95%CI=0.064-0.206,P<0.001),the lowest incidence of PTMC was in hyperfunctional thyroid nodule(OR=0.085,95%CI=0.019-0.379,P=0.001).According to multivariate logistic regression,multinodular goiter(OR=0.102,95%CI=0.055-0.189,P<0.001)and hyperfunctional thyroid nodule(OR=0.090,95%CI=0.020-0.401,P=0.002)can be considered as potential independent negative predictors for PTMC.【Conclusion】Sex and age are not statistically related to the incidence of PTMC in presumed benign thyroid diseases.The incidence of PTMC is highest in multinodular goitre and lowest in patients with Graves disease.It is acceptable that multinodular goitre and Graves disease can be considered as potential independent predictors of PTMC.
作者 黄卓雅 廖鹏娟 欧阳考滨 钟国方 苏桂晓 黄楚楚 HUANG Zhuo-ya;LIAO Peng-Juan;OUYANG Kao-bin;ZHONG Guo-fang;SU Gui-xiao;HUANG Chu-chu huang(Department of Pathology,the Huizhou Municipal Central Hospital,Huizhou Guangdong 516001,China)
出处 《武警后勤学院学报(医学版)》 CAS 2021年第6期17-21,共5页 Journal of Logistics University of PAP(Medical Sciences)
基金 吴阶平医学基金会临床科研专项资助基金(编号:320.6750.1989-87)。
关键词 甲状腺 乳头状癌 微小 结节性甲状腺肿 淋巴细胞性甲状腺炎 Thyroid gland Papillary carcinoma Tiny Nodular goiter Lymphocytic thyroiditis
  • 相关文献

参考文献13

二级参考文献97

  • 1陈福进,李秋梨,曾宗渊,宋明,杨安奎,张诠.分化型甲状腺癌的治疗及影响复发的因素分析[J].癌症,2004,23(11):1311-1316. 被引量:50
  • 2范西红,贺青卿,范子义,张小桥.甲状腺微小癌的诊断和治疗[J].中华肿瘤防治杂志,2007,14(19):1480-1482. 被引量:19
  • 3Davies L,Welch HG.Increasing incidence of thyroid cancer inthe United States,1973-2002[J].JAM A,2006,295(18):2164-2167.
  • 4Leenhardt L,Grosclaude P,Ch6ri6-Challine L.Increasedincidence of thyroid carcinoma in France:a true epidemic orthyroid nodule management effects? Report from the FrenchThyroid Cancer Committee[J].Thyroid,2004,14(12):1056-1060.
  • 5Enewold L,Zhu K,Kon E,et al.Rising thyroid cancer incidencein the United States by demographic and tumor characteristics,1980-2005[J].Cancer Epidemiol Biomarkers Prev,2009,18(3):784-791.
  • 6American Thyroid Association(ATA)Guidelines Taskforce onThyroid Nodules and Differentiated Thyroid Cancer,Cooper DS,Doherty GM,et al.Revised American Thyroid Associationmanagement guidelines for patients with thyroid nodules anddifferentiated thyroid cancer[J].Thyroid,2009,9(11):1167-1214.
  • 7Tuttle RM,Ball DW,Byrd D,et al.Thyroid carcinoma[J].J Natl Compr Canc Netw,2010,8(11):1228-1274.
  • 8Brown RL,de Souza JA,Cohen EE.Thyroid cancer:burden ofillness and management of disease[J].J Cancer,2011,2:193-199.
  • 9Xing M.BRAF mutation in thyroid cancer[J].Endocr RelatCancer,2005,12(2):245-262.
  • 10Rajagopalan H,Bardelli A,Lengauer C,et al.Tumorigenesis:RAF/RAS oncogenes and mismatch-repair status[J].Nature,2002,418(6901):934.

共引文献3572

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部